{"symbol":"REGN","fiscalQuarter":"Q2-2017","reportDate":"2017-08-03","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2017","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 2.04%","keyNumbers":[{"metric":"EPS","actual":"$4.17","expected":"N/A","surprise":"+30.59%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They emphasized ongoing investment in R&D to drive future growth."],"summary":"Overall, management expressed confidence in their product pipeline and future prospects. However, they did not provide specific guidance for upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a strong EPS performance, exceeding expectations by over 30%. Despite this positive surprise, the stock fell by 2.04% in reaction, which may indicate investor concerns about future revenue or overall market conditions. The lack of guidance could also contribute to uncertainty among investors.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2017 earnings: EPS beat by 30.59%. Stock down 2.04%. Full breakdown."}}